Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Cantargia AB ( (SE:CANTA) ) is now available.
Cantargia AB announced promising results from its CANFOUR trial, showcasing the efficacy of nadunolimab in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC). The trial demonstrated notable survival benefits, particularly in patients previously treated with pembrolizumab, suggesting nadunolimab’s potential to improve outcomes in this patient group and highlighting its manageable safety profile. These findings support further exploration of nadunolimab’s benefits, especially for non-squamous NSCLC patients who have progressed on immune checkpoint inhibitors.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for cancer. The company is primarily involved in the research and development of therapies targeting the IL1RAP protein, with a significant focus on addressing unmet medical needs in oncology.
Average Trading Volume: 2,278,629
Current Market Cap: SEK281.9M
See more data about CANTA stock on TipRanks’ Stock Analysis page.